HALO: halozyme.com Price/Earnings to Growth Multiple

Symbol and logo of brand Halozyme Corp (HALO)

Halozyme Therapeutics (HALO) revenues are based on royalties from the use of the ENHANZE system, which, combined with the absence of geopolitical risks in Western markets, ensures stability. The PEG ratio captures the current valuation trend, where a metric value of 0.23 confirms the potential. Licensing alliances with pharma behemoths are accelerating the adoption of subcutaneous therapy, expanding oncology treatment capabilities.

Price/Earnings to Growth Ratio: Halozyme Therapeutics, Inc. (HALO) for 07/04/2022 - 11/15/2026

Analytical breakdowns for Halozyme (HALO)

- share price and consensus valuation forecast:
General company analysis:HALO Halozyme Corp
Mass-produced product of halozyme.com

Amidst fierce patent battles in the drug delivery niche, Halozyme Therapeutics (HALO) risks losing contracts due to the budgets of biotech behemoths. This indicator for identifying undervalued growth companies compares the current P/E ratio with earnings growth rates, allowing for the daily tracking of an asset's market undervaluation when the value falls below one, which is critical for the timely detection of a trend reversal.

Competitors of Halozyme Therapeutics

Price/Earnings to Growth Multiple BeiGene Ltd ONC|PEG Multiple RVMD (revmed.com)|AAPG - Price/Earnings to Growth Multiple|CGON: Price/Earnings to Growth Multiple|URGN - PEG Multiple|Bicara Bio (BCAX) - Price/Earnings to Growth Ratio|Personalis Corp - Growth-Adjusted Payback Ratio|ERAS (Erasca Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Delcath Systems, Inc. DCTH|Price/Earnings to Growth Multiple YMAB (Y-mAbs Corp)|PEG Multiple Aura Bio (AURA)|PEG Multiple CADL (Candel Therapeutics Inc.)|ARAY - Price/Earnings to Growth Multiple|SLS - Price/Earnings to Growth Ratio|Actuate Therapeutics - Company Value to Earnings Growth Ratio|CTOR: PEG Multiple|TuHURA (HURA) - PEG Multiple|TARA (Protara Therapeutics Inc) - PEG Multiple|FATE: Growth-Adjusted Payback Ratio|PEG Multiple WHWK|TCRX (TScan) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Champions Oncology, Inc. CSBR|XBIT - Price/Earnings to Growth Multiple|CEL-SCI - PEG Multiple|OSTX - PEG Multiple|Radiopharm Theranostics Limited (RADX) - Price/Earnings to Growth Ratio|ARTV - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ANL|Price/Earnings to Growth Ratio VERU|PEG Multiple TPST|XLO: Market Cap to Earnings and Growth Ratio|PEG Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Price to Earnings Adjusted for Growth Rate|Kairos Pharma Ltd - PEG Multiple|Market Cap to Earnings and Growth Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Price/Earnings to Growth Ratio|CRIS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple APLM|Tharimmune (THAR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc.)|Genprex - Growth-Adjusted P/E Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Price/Earnings to Growth Multiple|Xenetic Bio - PEG Multiple|SLRX - PEG Multiple|PPBT: PEG Multiple|Growth-Adjusted P/E Ratio AONC|BGNE (BeiGene Ltd) - PEG Multiple|CKPT (Checkpoint Therapeutics, Inc) - Company Value to Earnings Growth Ratio|PEG Multiple ELEV|Price/Earnings to Growth Multiple iCAD Corp ICAD|Price/Earnings to Growth Ratio ikenaoncology.com IKNA|NTBL - Price/Earnings to Growth Multiple|VIRX - Price/Earnings to Growth Ratio|MOR - PEG Multiple|NAYA: PEG Multiple|Ascentage Pharma Group (AAPGV) - PEG Multiple